In the third quarter, Eli Lilly's sales grew by 20% year over year to $11.4 billion, largely thanks to Zepbound and Mounjaro.

The Carroll County Community Foundation is pleased to announce the recipient of the 2025 Lilly Endowment Community ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

Leveraging insights from OpenAI’s ChatGPT, Finbold has curated a $1,000 stock portfolio designed to capture growth ...

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...

Both Eli Lilly and Novo Nordisk have invested in GLP-1 injectables ... designed to help relieve manufacturing bottlenecks for injectable GLP-1 drugs Mounjaro and Zepbound. The company doubled its ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...